Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, has announced the signing of a strategic alliance agreement with Springer Nature, the publisher of the prestigious scientific journal, Nature.

The new alliance will see the two companies use their joint expertise and knowledge to support researchers across the global scientific community to speed up PCR diagnostic testing of important but various disease areas. 

PCR molecular diagnostics companies develop only a few diagnostic products annually. By leveraging the Springer Nature network, the two companies will provide funding and technology to global scientists and experts in various fields, significantly broadening the range and potential of diagnostic products. This initiative, spearheaded by senior management at both companies, builds upon the success of the Open Innovation Program that was launched by the two companies in 2023 whose goal was to develop innovative diagnostic products with participation of the scientific community.

Both companies will expand their collaboration using the OneSystem business by identifying and promoting potential partners as well as co-hosting annual symposiums starting with a joint declaration this year. 

"We have high expectations for the Open Innovation Program to contribute to the democratisation of PCR molecular diagnostics," said Marc Spenlé, COO of Springer Nature. "Together with Seegene, we will create an ecosystem that encourages and accelerates the development of new tests to address currently unmet needs."

Image caption- From left: Marc Spenlé, COO of Springer Nature; Frank Vrancken Peeters, CEO of Springer Nature; Dr Jong-Yoon Chun, CEO and Founder of Seegene; and Jun B. Kim, EVP and Global Head of Seegene OneSystem Business